How much funding has LTZ Therapeutics raised?

LTZ Therapeutics has raised $68.0M in total funding, most recently a Series B round.

Who are LTZ Therapeutics's investors?

LTZ Therapeutics's investors include Hillhouse Capital, Qiming VP, Lanchi Ventures, Unicorn Capital Partners, Shunwei Capital, Boyu Capital.

When was LTZ Therapeutics founded?

LTZ Therapeutics was founded in 2022.

Where is LTZ Therapeutics headquartered?

LTZ Therapeutics is headquartered in Shenzhen, China.

What industry is LTZ Therapeutics in?

LTZ Therapeutics operates in Biotech, Healthcare.

How many employees does LTZ Therapeutics have?

LTZ Therapeutics has 11-50 employees.

LTZ Therapeutics

Lift to Zenith with Novel Myeloid Engager Therapeutics

Shenzhen, China · Founded 2022 · $68.0M raised

Biotech

Healthcare

Headquarters: Shenzhen
Employees: 11–50
Founded: 2022
Business Model: B2B

Website: ltztherapeutics.com
Total Funding: $68.0M
Last Round: $38.0M Series BApr 2026
Rounds: 4

About

LTZ Therapeutics is a clinical-stage, immunotherapy-focused biotechnology company pioneering a novel Myeloid Engager Platform to treat oncology and autoimmune diseases. Founded in 2022 and headquartered in Redwood City, California with operations in Shenzhen, China, the company applies reverse translational science to develop Universal Myeloid Cell Engager (U-MCE)-based therapies targeting unmet clinical needs in cancer immunology.

Summary

LTZ Therapeutics is a Biotech company based in Shenzhen, China, founded in 2022. It has raised $68.0M in total across 4 rounds, most recently a $38.0M Series B round in Apr 2026. Investors include Hillhouse Capital, Qiming VP and Lanchi Ventures.